TG4010

Published

dm+d

Unassigned

New Medicines

Advanced non-small cell lung cancer (NSCLC) - first-line in combination with nivolumab and chemotherapy in patients with <50% of tumor cells expressing PD-L1

Information

New molecular entity
Transgene
Transgene

Development and Regulatory status

Discontinued
Discontinued
Discontinued
Dec 19Transgene decides to stop further development of TG4010 as the PII trial of TG4010, chemotherapy and nivolumab (NCT03353675) failed to meet its primary endpoint [20].

Category

Therapeutic vaccine
More than 39,000 new cases of lung cancer are diagnosed in the UK each year. NSCLC accounts for 85% of cases. [7]
Advanced non-small cell lung cancer (NSCLC) - first-line in combination with nivolumab and chemotherapy in patients with <50% of tumor cells expressing PD-L1
Subcutaneous